Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
10.1155/2019/9084643 44 LojoN.RasicZ.Zenko SeverA.KolencD.VukusicD.DrmicD.et al (2016)
Unlabeled vials lead to dangerous confusion, especially if you work with multiple peptides like BPC-157 , TB-500 , or semaglutide simultaneously
Its the pure, stable, powdered form of the compound before its brought back into a liquid solution through reconstitution
Signaling by gasotransmitters
B12 injections provide cyanocobalamin, a form of vitamin B12, to help treat or prevent low B12 levels
discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data
US$ 21.81
US$ 25.29
US$ 26.68
US$ 21.66
US$ 27.44
US$ 23.81
US$ 24.43
US$ 22.41
US$ 28.82
US$ 20.92
US$ 22.73